ArticleJournal of gastrointestinal cancer2026

Real-World Study of anti-PD-1 Combined with Regorafenib and Raltitrexed as Third-Line Therapy in Colorectal Cancer.

Yi Yu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.